Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Dilutive issuance
confidence 92%
filed 2026-06-18
Item 1.01
Epsilon Energy entered into an at-the-market (ATM) sales agreement with Roth Capital Partners authorizing the sale of up to $15 million in common shares. This is a dilutive equity issuance mechanism that allows the company to raise capital through registered offerings at prevailing market prices. The material nature of the $15 million authorization and the equity dilution to existing shareholders makes this a significant capital-raising event that would affect investor assessment of the company's financing strategy and shareholder ownership.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-06-18
EX-99.1
NetClass Technology Inc. has entered into a Technical Development Service Agreement with Bangyuan Liu to issue 2,800,000 ordinary shares as consideration for software development services over a one-year engagement, with issuance required by May 31, 2026.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-06-18
EX-99.2
NetClass Technology Inc. has agreed to issue 3,200,000 Class A ordinary shares to Akaewood Investment Holding Co., Ltd. as consideration for AI-based technology R&D services over a 12-month term.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-18
Item 3.02
KKR FS Income Trust issued 2,785,366.442 Class I shares for approximately $81.276 million in an unregistered private offering under Section 4(a)(2) and Regulation D to accredited investors, diluting existing shareholder ownership.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-18
Item 3.02
Graf Global Corp. issued Class A Ordinary Shares upon conversion of Class B Ordinary Shares, relying on Section 3(a)(9) exemption from Securities Act registration. The Sponsor and three board members irrevocably converted 5,749,999 Class B shares into Class A shares on a one-for-one basis, reducing Class B shares outstanding from 5,750,000 to 1, representing a material change in capital structure and shareholder voting/economic rights.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-18
Item 3.02
KKR FS Income Trust Select issued 183,883.440 Class I shares for approximately $4.597 million pursuant to a continuous private offering under Section 4(a)(2) and Regulation D to accredited investors.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-18
Item 3.02
Simultaneously with the IPO closing, Yorkville issued 6,300,000 unregistered warrants (4,000,000 to the Sponsor and 2,300,000 to CCM) at $1.00 per warrant pursuant to Section 4(a)(2) exemption, materially diluting existing and new shareholders' ownership interests.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-18
Item 3.02
Stellus Private Credit BDC disclosed an unregistered sale of 330,687 common shares for $5,000,000 pursuant to Section 4(a)(2) and Regulation D, structured as capital drawdowns under subscription agreements with existing investors. This is a classic dilutive issuance of equity securities exempt from registration, material to investors assessing the company's capital structure and shareholder dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-18
Item 8.01
The filing discloses a Sales Agreement with A.G.P./Alliance Global Partners authorizing an at-the-market (ATM) offering of up to $75 million in Class A common stock shares. This is a dilutive equity issuance under Rule 415(a)(4) of the Securities Act, registered on Form S-3 and declared effective June 4, 2026. ATM offerings are material capital-raising events that dilute existing shareholders and signal the company's liquidity needs.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-18
EX-99.1
Alvotech announced the closing of a public offering of 26,066,667 ordinary shares at $3.75 per share (raising ~$98 million gross) plus a concurrent private placement of 17,826,666 shares at the same price (raising ~$67 million gross), for total gross proceeds of approximately $165 million. This represents a substantial dilutive equity issuance that increases the share count from approximately 346.5 million to 390.4 million shares, materially affecting existing shareholders' ownership percentages and earnings per share.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-18
RedHill Biopharma announced a private placement of 8,571,429 ADSs at $0.70 per ADS with accompanying Series A-1 and A-2 warrants, generating $6 million upfront with up to $13.4 million in potential proceeds from warrant exercise. This is an unregistered equity issuance under Section 4(a)(2) and Regulation D, representing a dilutive capital raise typical of small-cap biopharmaceutical companies. The filing explicitly notes the securities have not been registered under the Securities Act and references a resale registration statement, confirming the private placement structure.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-18
PRF Technologies entered into a Standby Equity Purchase Agreement with Yorkville on June 18, 2026, granting the right to sell up to $15.0 million of ordinary shares over 36 months at 97% of the lowest three-day VWAP. This is a classic PIPE-like arrangement (private placement of equity) that creates dilution risk to existing shareholders. The company also issued 20,276 commitment shares immediately as a fee. The filing explicitly notes this is an unregistered private placement under Section 4(a)(2) and Regulation D, and references prior similar activity (May 2026 agreement for $10.0 million). This is material to investors as it signals capital-raising pressure and future dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-18
Item 3.02
The filing discloses an unregistered sale of $40 million in common shares pursuant to capital call notices delivered to investors under subscription agreements, relying on Section 4(a)(2), Regulation D, and/or Regulation S exemptions. This is a classic dilutive private placement that would materially affect investor assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-18
Item 3.02
AB Private Lending Fund completed an unregistered sale of 2,060 Class I common shares of beneficial interest to feeder vehicles, exempt under Section 4(a)(2) and Regulation S, materially affecting the capital structure and ownership interests of existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-18
Item 1.01
Faeth Therapeutics entered into an at-the-market (ATM) offering agreement with TD Securities on June 18, 2026, authorizing the sale of up to $150 million in common stock shares, representing a classic dilutive equity issuance that signals potential capital needs and future shareholder dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 72%
filed 2026-06-18
Item 8.01
Automatic conversion of 24,435.594 shares of Series B Non-Voting Convertible Preferred Stock into 24,435,594 shares of Common Stock materially increased the outstanding share count to 25,778,754 shares, resulting in significant dilution to existing shareholders' ownership percentages and earnings per share.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-18
EX-99.1
Sagtec Global Limited issued 1,500,000 Class A Ordinary Shares to CEO and major shareholder Ng Chen Lok at US$1.04 per share (US$1.56 million aggregate) in a private placement of unregistered, restricted securities with no registration rights.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-06-18
Globavend entered into a Standby Equity Purchase Agreement (SEPA) on June 16, 2026, with YA II PN, Ltd. for the purchase of up to $20 million of ordinary shares over 36 months. This is a committed equity financing arrangement where the company can draw down capital by issuing shares at a discount to market price (93–96% of VWAP), subject to registration. The structure and mechanics—discretionary advances, volume-weighted pricing, and a $20 million commitment—are characteristic of a PIPE-like dilutive equity issuance used to raise capital.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-18
Item 1.01
SS Innovations entered into an ATM Sales Agreement with Virtu Americas LLC on June 18, 2026, to sell up to $50 million of common stock through an "at the market offering" program. This is a classic dilutive equity issuance that would materially affect existing shareholders through potential dilution and is a significant capital-raising activity for the company.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-18
Item 3.02
The Company completed an unregistered private placement of 600,000 Class A Ordinary Shares to the Sponsor at $10.00 per share ($6 million gross proceeds) pursuant to Section 4(a)(2) of the Securities Act, simultaneously with the IPO closing. This is a material dilutive issuance typical of SPAC sponsor equity stakes.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-18
EX-99.2
IceCure completed a $5.5 million private placement of 1,833,334 ordinary shares plus Series D and E Warrants to a healthcare-focused institutional investor at $3.00 per share, issued under Section 4(a)(2) exemption.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-18
Item 8.01
The filing discloses a registered public offering of 38,333,333 shares of common stock (including full exercise of the underwriter's over-allotment option) generating approximately $63.25 million in gross proceeds. This is a material dilutive equity issuance that would significantly affect a reasonable investor's assessment of ownership dilution and the company's capital structure. The offering was conducted pursuant to an effective Form S-1 registration statement, making this a registered public offering rather than an unregistered private placement.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-18
Item 2.03
Item 3.02 discloses an unregistered private placement of a Pre-Funded Warrant to Tether issued on June 18, 2026 as consideration for transfer of 50% of a receivable under an existing loan. The warrant was issued without Securities Act registration under Section 4(a)(2) and Regulation D Rule 506(b) exemptions, representing a dilutive equity issuance to an accredited investor. This is a material capital structure event affecting shareholder equity.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-18
EX-99.1
The press release announces a private placement of $6.5 million in ordinary shares (or pre-funded warrants) and ordinary warrants to accredited and institutional investors under Section 4(a)(2) and Regulation D exemptions. This is an unregistered equity issuance that will dilute existing shareholders, with 1,857,143 ordinary shares and accompanying warrants being issued at $3.50 per share. The company explicitly states it has entered into definitive securities purchase agreements and expects closing on June 23, 2026.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-06-18
Item 1.01
Hyperscale Data entered into an At-the-Market (ATM) Issuance Sales Agreement on June 18, 2026, to sell up to $300 million of Class A common stock through Spartan Capital Securities. The offering is a registered equity issuance that will be dilutive to existing shareholders' ownership percentages and voting power, with proceeds earmarked for facility development, Bitcoin acquisition, and precious metals purchases.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-18
Item 1.01
CervoMed entered into a Securities Purchase Agreement for a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, raising $10 million in gross proceeds. The offering includes placement agent warrants equal to 6.0% of shares issued and represents a material dilutive equity issuance to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-18
Item 3.02
The Company issued 545,591 shares of common stock to Lind Global Asset Management in satisfaction of payment obligations under a $7.5 million senior secured convertible promissory note. The issuances occurred on June 17, 2026 and May 19, 2026, relying on Section 3(a)(9), Section 4(a)(2), and/or Regulation D exemptions. This is a dilutive equity issuance to an existing securityholder in connection with debt repayment obligations, which materially affects share count and ownership structure.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-18
The 6-K discloses a private placement of 862,069 ordinary shares at $0.58 per share for $500,000 aggregate proceeds, executed pursuant to Regulation S. The Securities Purchase Agreement includes a 24-month lock-up on further issuances and registration statements, which is characteristic of dilutive equity financing. This unregistered sale of equity securities is material to investors assessing capital structure and ownership dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-06-18
The filing discloses multiple material events, but the dominant theme is substantial dilutive equity issuances. Item 3.02 reports unregistered sales of common stock totaling approximately 3.8 million shares issued to lenders and preferred stockholders (Streeterville and 1800 Diagonal) in conversion transactions and exchanges occurring June 15-17, 2026. Item 1.01 describes entry into three debt instruments (Quick Capital Note, 1800 Diagonal Note, and Streeterville exchanges) with conversion rights that trigger further dilution. While the filing also involves debt covenant obligations (Item 2.03), the primary disclosed activity centers on the issuance of unregistered equity securities as consideration for debt restructuring and preferred stock conversions, which is characteristic of dilutive_issuance events at small-cap issuers under financial stress.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-18
The filing discloses a Stock Purchase Agreement (Item 1.01) under which NextNRG issued 260,000 shares of common stock to CEO Michael D. Farkas at $0.386 per share in exchange for debt forgiveness of $100,360. This is a dilutive equity issuance to an insider (the CEO and significant stockholder) in lieu of cash payment, which is a material capital structure event. The concurrent termination of the underlying promissory note (Item 1.02) confirms the debt-for-equity nature of the transaction.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-18
Item 1.01
Item 1.01 discloses a private placement of shares ("Shares") offered and issued under Section 4(a)(2) and Regulation D exemptions, with an Amendment No. 1 to Registration Rights Agreement dated June 18, 2026. The filing explicitly states the Shares were unregistered and issued without general solicitation, which is characteristic of a dilutive equity issuance. The forward-looking statements reference risks related to executing growth strategy and maintaining listing compliance, consistent with a capital raise by a smaller-cap company.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-18
The filing discloses a completed public offering of 1,040,000 shares of common stock and 2,960,000 pre-funded warrants (exercisable for common stock) for aggregate gross proceeds of $3.2 million, consummated on June 16, 2026 under Item 1.01. The pre-funded warrants are immediately exercisable at $0.007 per share and represent substantial dilution to existing shareholders. This is a material equity issuance that would affect investor assessment of ownership and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-18
Item 3.02
Bandwidth Inc. issued $316.25 million aggregate principal amount of 0% convertible senior notes due 2032 in a private placement under Rule 144A and Section 4(a)(2), with conversion into up to 5,986,169 shares of Class A common stock at an initial conversion price of approximately $72.64 per share, creating substantial dilution potential for existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-06-18
Item 8.01
New Mountain Finance Corp entered into a Seventh Supplement to its Note Purchase Agreement authorizing the issuance of $150 million in aggregate principal amount of senior notes ($40M Tranche A, $35M Tranche B, $75M Tranche C) in a private placement relying on Section 4(a)(2) of the Securities Act. The issuance will be used for general corporate purposes, investments, and debt repayment, materially increasing the Company's leverage.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-18
Item 1.01
Commercial Vehicle Group entered into a Capital on Demand™ Sales Agreement with JonesTrading to offer and sell up to $25 million of common stock "at the market" under Rule 415(a)(4). This is a registered direct offering of equity securities that creates potential dilution to existing shareholders. The $25 million offering size and the at-the-market structure are material to investors assessing capital structure and ownership dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-06-18
Item 3.02
The filing discloses Item 3.02 (Unregistered Sales of Equity Securities) with a cross-reference to Item 8.01 for substantive details. Item 3.02 is the dedicated disclosure item for dilutive equity issuances such as private placements and PIPEs. While the actual transaction details are incorporated by reference to Item 8.01 (not shown in this excerpt), the presence of Item 3.02 itself signals an unregistered equity sale, which is material to investors as it affects share dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-18
Item 1.01
IIOT-OXYS entered into Amendment No. 1 to a Securities Purchase Agreement on June 12, 2026, authorizing issuance of up to 167 shares of Series D Convertible Preferred Stock, with a Third Additional Closing on June 16, 2026 issuing 30 shares (27 purchased + 3 as equity incentive) to accredited investor GHS under Section 4(a)(2) and Regulation D Rule 506(b). This unregistered private placement of preferred stock materially dilutes existing shareholders and affects the registrant's capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-06-18
Item 1.01
Tianci International consummated a registered public offering of 6,055,000 units (4,055,000 standard units and 2,000,000 pre-funded units) at $0.81 per unit on June 17, 2026, generating approximately $4.9 million in gross proceeds. Each unit includes common stock (or pre-funded warrant) and common warrants with anti-dilution provisions, materially diluting existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-18
Item 8.01
The filing discloses an At Market Issuance Sales Agreement (ATM) under which Sonoma Pharmaceuticals may offer and sell shares of common stock through an agent. The company has already sold 173,073 shares for $574,633 and increased the aggregate offering price to $3,641,703 as of the filing date. ATM offerings are classic dilutive equity issuances that signal capital-raising activity and potential shareholder dilution, material to investors assessing ownership stakes and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-18
Item 3.02
Carlyle Credit Solutions completed an unregistered sale of 322,258 shares of Class I common stock for $5.9 million under Section 4(a)(2) and Regulation D exemptions, increasing outstanding shares from approximately 95.1 million to 95.4 million and materially affecting shareholder ownership and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-18
The filing's primary disclosure under Item 3.02 concerns the conversion of convertible promissory notes into common stock. Between June 12–17, 2026, holders converted approximately $663,188 of debt into 2,444,447 shares of common stock issued without Rule 144 restrictive legends. This represents a material dilutive issuance of equity securities that would affect a reasonable investor's assessment of ownership and capital structure, even though the conversions were pursuant to previously disclosed securities purchase agreements from 2025.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-18
Item 3.02
Blue Owl Real Estate Net Lease Trust sold 4,023,007 shares of Class I common shares for approximately $43.0 million in an unregistered offering exempt under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-18
Item 3.02
Blue Owl Digital Infrastructure Trust sold 3,203,718 common shares across multiple classes for approximately $33.2 million in gross proceeds on June 1, 2026, pursuant to Section 4(a)(2), Regulation D, and/or Regulation S exemptions from registration under the Securities Act of 1933.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-17
Item 3.02
The filing discloses unregistered issuances of Common Stock on three dates (May 12, May 28, and June 15, 2026) totaling approximately 308,679 shares in exchange for redemptions of Series A1 and Series A Preferred Stock. The conversion prices declined sharply from $6.36 to $5.41 to $4.30 per share over the period, indicating deteriorating valuation. These are classic dilutive equity issuances that would materially affect shareholder ownership and are properly classified under Item 3.02.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-17
EX-99.2
Alvotech announced and priced a $152 million underwritten public offering of 22.67 million ordinary shares at $3.75 per share, concurrent with a private placement of 17.83 million shares to European investors at the same price. The combined offering raises approximately $152 million in gross proceeds and significantly increases share count, with proceeds intended for development, working capital, and potential debt repayment.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-17
Item 8.01
NeoGenomics disclosed the pricing of a convertible senior notes offering to qualified institutional buyers under Rule 144A. Convertible notes are inherently dilutive securities that can be converted into equity, making this a material capital-raising event that would affect investor assessment of share dilution and the company's financing strategy.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-17
Item 1.01
DUOS Technologies entered into an underwritten registered direct offering of 2,000,000 shares of common stock and 3,800,000 pre-funded warrants (exercisable at $0.001) for approximately $55 million in gross proceeds. The combination of a substantial equity issuance and highly dilutive pre-funded warrants represents a material capital raise that will significantly dilute existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-17
Item 3.02
Pubco completed an unregistered private placement sale of equity securities to the Foundation under Section 4(a)(2) of the Securities Act in connection with the business combination.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-17
EX-99.2
NOVONIX announced a material capital raising comprising an institutional placement of 129,334,163 ordinary shares at A$0.16 per share (a 31.2–33.3% discount to market prices) under ASX Listing Rule 7.1 placement capacity, together with a non-underwritten share purchase plan (SPP) offering up to 18,750,000 shares to eligible shareholders at the same price. The placement and SPP are expected to raise approximately A$23.7 million in aggregate, directed toward capital expenditure and production capacity expansion.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-17
Item 1.01
Smartbird amended its Securities Purchase Agreement to increase the aggregate principal amount of senior secured convertible notes from $50.0 million to $100.0 million, with conversion into Class A common stock at $4.00 per share, representing a material dilutive issuance of convertible securities.
View raw filing on EDGAR →